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Estrogens are potent regulators of mature hema-
topoietic cells; however, their effects on primitive
and malignant hematopoietic cells remain unclear.
Using genetic and pharmacological approaches,
we observed differential expression and function of
estrogen receptors (ERs) in hematopoietic stem cell
(HSC) and progenitor subsets. ERa activation with
the selective ER modulator (SERM) tamoxifen in-
duced apoptosis in short-term HSCs andmultipotent
progenitors. In contrast, tamoxifen induced prolife-
ration of quiescent long-term HSCs, altered the
expression of self-renewal genes, and compromised
hematopoietic reconstitution after myelotoxic stress,
which was reversible. In mice, tamoxifen treatment
blocked development of JAK2V617F-induced myelo-
proliferative neoplasm in vivo, induced apoptosis of
human JAK2V617F+ HSPCs in a xenograft model, and
sensitized MLL-AF9+ leukemias to chemotherapy.
Apoptosis was selectively observed in mutant cells,
and tamoxifen treatment only had a minor impact
on steady-state hematopoiesis in disease-free ani-
mals. Together, these results uncover specific regu-
lation of hematopoietic progenitors by estrogens
and potential antileukemic properties of SERMs.
INTRODUCTION
In adult mammals, hematopoietic stem cells (HSCs) reside in a
complex bone marrow (BM) microenvironment where they res-
pond to multiple extracellular signals (Mercier et al., 2012).
HSCs are associated with perivascular niches (Kiel et al., 2005;
Me´ndez-Ferrer et al., 2010) and are exposed to signals trans-
ported by the circulatory system, including hormones. Estrogens
are potential HSC niche modulators given their bone anabolic
properties (Colaianni et al., 2012; Compston, 2001; Hughes
et al., 1996; Nakamura et al., 2007).
Estrogens regulate lymphopoiesis. ERa is expressed by B cell
precursors (Smithson et al., 1995), thymocytes (KawashimaCellet al., 1992), and CD8+ T cells (Stimson, 1988), while ERb is ex-
pressed in thymus and spleen (Kuiper et al., 1997; Mosselman
et al., 1996). Mice deficient in ERa have fewer BM B cells,
whereas pharmacological treatment with the natural ER agonist
17b-estradiol (E2) depletes lymphoid-restricted progenitors and
B/T cell precursors (Medina et al., 2001; Thurmond et al., 2000).
Data regarding effects of estrogens onmore primitive hemato-
poietic cells are somewhat conflicting. E2 was initially reported
to decrease lin c-kit+ Sca-1+ (LSK) HSPCs in mouse BM (Thur-
mond et al., 2000) but increase the number of vascular-associ-
ated HSPCs, likely through the regulation of stromal cells (Illing
et al., 2012). HSC division frequency is higher in female mice
than in male mice, and it is further increased by exogenous E2
administration or pregnancy, although these effects did not
change BM HSC numbers. In addition, estrogen signaling pro-
motes extramedullary hematopoiesis and erythropoiesis in the
spleen (Nakada et al., 2014).
Aberrant estrogen signaling might contribute to leukemogen-
esis because mice deficient in ERb develop chronic myeloprolif-
erative disease during aging (Shim et al., 2003). Moreover,
women consistently exhibit lower incidence of hematological
cancers compared to men (American Cancer Society, 2013;
Cancer Research UK, 2013), strongly suggesting a contribution
of sex hormones in the development of suchmalignancies. How-
ever, whether estrogen signaling can directly control normal and
leukemic HSPCs has remained unclear. Outside the hematopoi-
etic system, ER activation stimulates the growth of solid tumors,
most prominently in breast cancer (Adkins et al., 1999; Roden-
huis et al., 2003; Tallman et al., 2003; Wang et al., 2004b), and
the selective ER modulator (SERM) tamoxifen is clinically used
to treat ER+ breast cancer and recurrent gliomas.
In this study we found that estrogen signaling differentially
regulates survival, proliferation, and self-renewal of normal and
malignant HSPCs. Furthermore, our data demonstrate that ther-
apeutic targeting of this pathway with the SERM tamoxifen could
be a valuable strategy for blocking the development of chronic
myeloproliferative neoplasms (MPNs).
RESULTS
Expression of ERs in Hematopoietic Progenitors
To determine whether HSPCs might be directly regulated by es-
trogens, ER expression was analyzed in purified hematopoieticStem Cell 15, 791–804, December 4, 2014 ª2014 Elsevier Inc. 791
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Regulation of Hematopoiesis and MPN by Estrogenscells. Esr1 (ERa) and Esr2 (ERb) mRNA and proteins were differ-
entially expressed by distinct HSPC populations. Intriguingly,
Esr1 expression was very high in long-term HSCs (LT-HSCs)
andmultipotent progenitors (MPPs) and lower in committed pro-
genitors and mature lineages. In contrast, Esr2 expression was
very low or undetectable (Figures 1A–1C), in agreement with
public gene expression data (Figure S1A available online). Esr1
expression was similar in HSPCs from male and female mice
(data not shown).
ERa-deficient (Esr1/) mice had reduced BM LT-HSCs and
short-term HSCs (ST-HSCs), but similar levels of MPPs, mega-
karyocyte precursors (lin c-kit+ Sca-1 CD41+), and CD41+
megakaryocytic cells (Figure 1D and data not shown). However,
ERa or ERb were not required for long-term multilineage recon-
stitution after BM transplantation, and Esr1/BMcells exhibited
only a partial reduction in short-term engraftment (Figures 1E
and 1F). This suggested differential roles of estrogen signaling
in specific HSPC subsets.
Estrogen Signaling Differentially Regulates Survival and
Proliferation of Hematopoietic Progenitors
We administered tamoxifen to male mice to avoid the confound-
ing effects of variably high endogenous estrogens in females.
Surprisingly, treatment of WT mice with tamoxifen at a dose
typically used to induce CreER recombinases caused a rapid
reduction in BM cellularity (50%–60% of control as early as
1 week; Figure 1G). However, except for reduced platelet
counts, most hematological parameters were normal in mice
chronically treated with tamoxifen (Table S1 available online),
suggesting mild effects on mature hematopoietic cells.
Tamoxifen rapidly reduced levels of LSK cells (Figures 1H
and S1B), preceding the decay in BM cell number. Interest-
ingly, differential effects were observed in distinct HSPC popu-
lations. While MPPs were 7-fold reduced, the decrease in
ST-HSCs and more mature myeloid progenitors was less pro-
nounced and LT-HSC numbers were relatively preserved (Fig-
ures 1I–1J and S1B). Further subfractionation revealed that
MPP4 and MPP3 (Wilson et al., 2008) were the most affected
populations. In contrast, the number of LT-HSCs, defined as
LSK CD150+ CD48 or LSK CD150+ CD48 CD34 CD135
cells, did not change after treatment (Figure S1C and data
not shown).
These effects were the result of specific changes in cell sur-
vival and proliferation. ST-HSC/MPP depletion by tamoxifen
was caused by apoptosis, whereas LT-HSCs and myeloid pro-
genitors were more resistant to apoptosis (Figure 1K; see also
Figure 5D). In a manner similar to that in males, tamoxifen also
decreased BM HSPCs by apoptosis in female mice (Figures
S1D and S1E). A more pronounced apoptotic effect on LT-
HSCs was observed in females, which might be related to their
higher proliferation rate (Nakada et al., 2014). Treatment of BM
lin cells in vitro with 4-hydroxytamoxifen (4OHT) also induced
apoptosis, suggesting a direct proapoptotic effect of tamoxifen
on HSPCs (Figure S1F).
While LT-HSCs were comparatively more resistant to tamox-
ifen-induced cell death, their proliferative fraction increased after
2 weeks of treatment (Figure 1L). These results indicate that sur-
vival and proliferation are differentially regulated by estrogens in
distinct HSPC subsets.792 Cell Stem Cell 15, 791–804, December 4, 2014 ª2014 Elsevier InThe Effects of Tamoxifen on HSPCs Are Direct and
Mediated by ERa
Gene expression profiling was performed by next-generation
sequencing (RNA-seq) in LT-HSCs, ST-HSCs, and MPPs iso-
lated from tamoxifen- or vehicle-treated mice. Principal com-
ponent analysis showed a coherent clustering of biological
replicates (Figure 2A), indicating that tamoxifen treatment did
not cause a global deregulation of gene expression profiles.
Instead, tamoxifen caused coordinated changes in the expres-
sion of genes associated with HSC self-renewal, cell cycle,
signal transduction, and metabolism, as revealed by gene-set
enrichment analysis (GSEA) (Krivtsov et al., 2006; Subramanian
et al., 2005). Few changes were common to all three HSPC
populations, consistent with their differential in vivo responses.
Most differentially expressed gene sets were downregulated in
LT-HSCs but upregulated in ST-HSCs and/or MPPs (Figures
2B and S2).
Tamoxifen can function as an ER agonist/antagonist in a
cell-type- and context-dependent manner. To characterize its
ligand activity in HSPCs, we analyzed how tamoxifen affected
the expression of genes positively or negatively regulated by
the native ER agonist E2 in other tissues (Frasor et al., 2003;
Ghosh et al., 2000; Laganie`re et al., 2005; Wang et al.,
2004a). Globally, these genes exhibited similar changes in
LT-HSCs upon tamoxifen treatment—E2-induced genes were
upregulated and E2-repressed genes showed decreased
expression—suggesting an ER agonist action of this SERM
on LT-HSCs (Figure 2C). E2-induced genes were upregulated
by tamoxifen in all three HSPC populations, but E2-repressed
genes were specifically downregulated in LT-HSCs (Figure S2),
which could be related to reduced levels of ER corepressors
in ST-HSCs/MPPs compared to LT-HSCs (Figure S3A). These
results suggest that tamoxifen has ER agonistic activity in
HSPCs, where it activates or represses genes in a cell-type-
specific manner.
To confirm that these effects were mediated by canonical ER
signaling, pharmacological studies were performed in mice lack-
ing ERs. Tamoxifen reduced ST-HSC and MPP numbers by
apoptosis in control and Esr2/, but not in Esr1/, mice. In
addition, LT-HSC cycle entry caused by tamoxifen was mostly
abolished in the absence of ERa (Figures 2D–2F). In order to
clarify whether these effects were direct or mediated by the
BM microenvironment, WT recipient mice were transplanted
with WT or Esr1/ BM cells, allowed to engraft for 4 months,
and treated with tamoxifen or vehicle for 2 weeks. Tamoxifen-
induced changes were not observed in mice with Esr1/ hema-
topoiesis and thus were hematopoietic cell autonomous (Figures
2G and 2H). Given the reduction in platelet counts observed
in treated mice, we analyzed the effect of tamoxifen on mega-
karyocytic precursors. This population was also depleted by
apoptosis in an ERa-dependent, cell-autonomous fashion (Fig-
ures 2G and 2H). These data indicate that tamoxifen can directly
regulate hematopoietic cell proliferation and survival through the
activation of ERa expressed by HSPCs.
ERaActivation Alters Gene Expression Patterns Related
to HSC Self-Renewal, Proliferation, and Apoptosis
LT-HSCs display a low proliferative rate (Morrison et al., 1995),
which allows for their long-term self-renewal (Wilson et al.,c.
Figure 1. Differential Regulation of HSPC Survival and Proliferation by Estrogen Signaling
(A and B) Relative mRNA expression of Esr1 and Esr2, measured by qPCR and normalized to that of Gapdh, in murine hematopoietic cell subsets. (C) Repre-
sentative western blot of Esr1 and Esr2 in sorted HSPCs.Mouse ovary, positive control. Values indicate densitometric ratios of Esr1/Actb, normalized to the ovary
sample. (D) HSPC numbers in the BM of maleWT, Esr1/, or Esr2/mice. (E and F) Competitive repopulation capacity of ER-deficient BM cells, measured over
time (E) as donor (CD45.2+) chimerism in peripheral blood and (F) as multilineage reconstitution in BM 11 months posttransplant. Lethally irradiated recipients
were transplanted with 106 WT or ER null BM cells and 106 B6.SJL (CD45.1+) competitor BM cells. (G) Number of total BM nucleated cells, (H) LSK cells, (I) HSPC
subpopulations, (J) colony-forming units in culture (CFU), (K) fraction of apoptotic (Annexin V+) cells in HSPC subpopulations, and (L) cell-cycle distribution of LT-
HSCs in the BM of male WT C57BL/6J mice after in vivo tamoxifen treatment for the indicated time frame (J, 8 days). Data are means ± SD. *p < 0.05, **p < 0.01,
***p < 0.001. Cell numbers correspond to two hind legs (G) or four limbs, sternum, and spine (D, H, and I). n = 3–6 (D–F), n = 5 (G, J, and K), n = 2–7 (H, I, and L). Data
in (A)–(F) show one of two independent experiments; (G)–(L) are representative of three or more experiments. CMP, commonmyeloid progenitors; CLP, common
lymphoid progenitors; CD19, B cells; CD90, T cells; Gr1-Mac1, mature myeloid cells; Blast, MLL-AF9+ AML blasts; FL, fetal liver; TAM, tamoxifen. See also
Figure S1 and Table S1.
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Figure 2. The Effects of Tamoxifen on HSPCs Are Mediated by ERa Expressed by Hematopoietic Cells
(A) Principal component analysis of gene expression profiling data (RNA-seq) of LT-HSCs, ST-HSCs, andMPPs from tamoxifen-treated or control male C57BL/6J
mice. Each dot represents one sample pooled from two mice. n = 3 replicates per condition.
(legend continued on next page)
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Regulation of Hematopoiesis and MPN by Estrogens2008). In parallel with their increased proliferation, a striking
feature of LT-HSCs from tamoxifen-treated mice was the loss
of gene expression patterns associated with self-renewal and
HSC identity (Figures 3A and S2 and Table S2 and Table S3).
GSEA revealed coordinated downregulation of the self-re-
newal-associated signature described for HSCs and leukemia
stem cells, the HSC-specific ‘‘fingerprint,’’ and genes positively
regulated by the polycomb ring-finger oncogene Bmi1; con-
versely, LT-HSCs from tamoxifen-treated mice showed in-
creased expression of genes repressed in self-renewing cells
and negatively regulated by Bmi1 (Arranz et al., 2012; Chambers
et al., 2007; Krivtsov et al., 2006).
Tamoxifen treatment also activated the transcriptional pro-
gram of the ER target Myc (Zeller et al., 2006), associated with
HSC differentiation and loss of self-renewal (Wilson et al.,
2004). Indeed, Myc and Myc-induced genes were upregulated
in tamoxifen-treated HSCs, whereas the expression of Myc-
repressed genes was mostly reduced (Figures 3B and 3C),
coincident with the induction of cell cycle progression genes
(Figure 3D). In addition, many of the genes upregulated by
tamoxifen in HSPCs were Myc targets (Figure S3B). Expression
of the chromatin remodeling factor Satb1, which represses Myc
and is required for HSC quiescence and self-renewal (Will et al.,
2013), was significantly downregulated by tamoxifen in both LT-
and ST-HSCs (Figure 3E). To determine whether HSPC changes
elicited by tamoxifen required Myc function, conditional Myc-
deficient mice (Pol2-creERT2;MycloxP/loxP) were treated with
tamoxifen chronically or only transiently, to activate CreERT2.
Myc-deficient MPPs did not undergo cell death upon chronic
tamoxifen treatment (Figure 3F), suggesting that Myc mediates,
at least partially, tamoxifen’s effects on HSPCs.
In addition, tamoxifen reduced the expression of the stem cell
factor receptor Kit specifically in LT-HSCs; c-kit protein levels
were also reduced by tamoxifen in the cell surface of WT or
Esr2-deficient LT-HSCs, but not in Esr1-deficient LT-HSCs (Fig-
ures 3G and 3H), indicating that this effect was also mediated
by ERa.
Consistent with our initial findings, ST-HSCs (but not LT-
HSCs) from tamoxifen-treated mice showed increased expres-
sion of proapoptotic genes (Aifm1 and Casp3) and reduced
levels of antiapoptotic genes (Cflar) (Figure S4A). These changes
were not observed in MPPs, probably due to their earlier
apoptosis and depletion (Figure S1B) or the selection of estro-
gen-resistant subpopulations (MPP1 and MPP2; Figure S1C).
Thus, tamoxifen impairs the self-renewal program of LT-HSCs
and induces apoptosis of more differentiated progenitors, at
least partially via ERa-mediated induction of Myc.(B) Gene sets significantly changed (FDR < 0.15) in at least one HSPC populatio
regulation, and no change, respectively, in tamoxifen-treated HSPCs. Figure S2
(C) Gene set enrichment analysis of estrogen target genes (genes previously repor
with tamoxifen/vehicle for 2 weeks.
(D–F) Number of (D) ST-HSCs/MPPs (per four limbs, sternum, and spine), (E) cell
the BM of male WT, Esr1/, or Esr2/ mice after in vivo tamoxifen/vehicle trea
(G and H) Number of (H) total BM nucleated cells and HSPC subsets, and (G) fract
WT or Esr1/ BM cells, engrafted for 4 months and treated with vehicle/tamoxi
Data are means ± SD. n = 2–7 (D–F), n = 5 (G and H). *p < 0.05, **p < 0.01, ***
enrichment score; FDR, Benjamini-Hochberg false discovery rate; MkP, megakary
Table S3.
CellTamoxifen Compromises Hematopoietic Recovery after
Myelotoxic Stress
To determine whether tamoxifen-induced changes in LT-HSC
proliferation and self-renewal might have functional conse-
quences, we studied the hematopoietic recovery of mice treated
with tamoxifen or vehicle and subsequently subjected to mye-
lotoxic regimens. Tamoxifen-treated mice exhibited defective
multilineage hematopoietic recovery after 5-fluorouracil (5-FU)
challenge (Figure 3I) and premature death upon sublethal irra-
diation (Figure S4B). To study the reversibility of these effects,
LT-HSCs from tamoxifen-treated mice were transplanted into
tamoxifen-free recipients. These cells exhibited unaltered ca-
pacity for long-term multilineage reconstitution in a normal envi-
ronment, demonstrating that the effects of tamoxifen can revert
in the absence of the ligand (Figure S4C).
In order to investigate whether the detrimental effect of tamox-
ifen onHSC function was also dependent on ERa, we studied the
hematopoietic recovery of tamoxifen/vehicle-treated Esr1/
mice after 5-FU administration. Unlike WT mice, tamoxifen-
treated Esr1/ mice exhibited normal reconstitution kinetics.
Thus, tamoxifen’s effects on HSC function are also mediated
by ERa (Figure 3I).
Tamoxifen Blocks the Development of
JAK2V617F-Induced MPNs
The differential effects of ER activation in HSPCs suggested a
potential use of SERMs to treat hematological malignancies
through a dual action: impairment of leukemia-initiating cells
and reduction of leukemic burden through apoptosis of leukemic
progenitors. Therefore we tested the potential therapeutic effect
of tamoxifen in amousemodel expressing a pointmutation of the
Janus kinase 2 (JAK2V617F) in HSCs, frequently found in patients
with MPNs (Baxter et al., 2005; James et al., 2005; Kralovics
et al., 2005; Levine et al., 2005). Male mice transplanted with
polyI-polyC-induced Mx1-cre;JAK2V617F BM cells, which
develop polycythemia vera-like MPN (Kubovcakova et al.,
2013; Tiedt et al., 2008), and disease-free control mice were
chronically treated with tamoxifen when granulocytosis and er-
ythrocytosis were detected in peripheral blood (Figure S5A).
Notably, tamoxifen treatment completely abolished MPN-as-
sociated neutrophilia and thrombocytosis, with no major side
effects in control mice (Figure 4A). Tamoxifen treatment also alle-
viated the early increase in red cell counts, hemoglobin, and
hematocrit; decreased BM megakaryocytes; and reduced
MPN-associated splenomegaly, with preservation of spleen ar-
chitecture and decreased infiltration of interfollicular areas by
megakaryocytes (Figures 4A–4C and S5B–S5F). Prolongedn after tamoxifen treatment. Red, blue, and gray indicate upregulation, down-
shows an extended version of this diagram.
ted to be induced or repressed by E2) in LT-HSCs from C57BL/6J mice treated
-cycle distribution of LT-HSCs, and (F) fraction of apoptotic ST-HSCs/MPPs in
tment for 2 weeks.
ion of apoptotic HSPCs in the BM of male WT C57BL/6J mice transplanted with
fen for 2 weeks. Data are representative of two independent experiments.
p < 0.001 (vehicle versus tamoxifen). ES, enrichment score; NES, normalized
ocyte precursors (lin c-kit+ Sca-1CD41+). See also Figure S2, Table S2, and
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Figure 3. Tamoxifen Compromises HSC Self-Renewal and Activation during Stress Hematopoiesis
(A, B, and D) Coordinated changes, determined by gene-set enrichment analysis, in genes associated with (A) HSC self-renewal, (B) Myc-regulated tran-
scriptome, and (D) cell-cycle progression in LT-HSCs isolated fromC57BL/6Jmice treatedwith tamoxifen/vehicle for 2 weeks. (C and E) Expression levels ofMyc
and Satb1 genes in BM HSPCs from C57BL/6J mice treated as in (A). Data are fragments per kilobase of exon per million mapped reads (FPKM) ± SD. n = 3.
Adjusted *p < 0.15, **p < 0.05. (F) Number of MPPs (per hind leg) in the BM of male Pol2-creERT2;MycloxP/loxP or control mice treated with tamoxifen for 4 weeks.
Horizontal lines indicate themean. n = 4. (G)mRNA expression levels ofKit, determined as in (C) and (E). (H) Surface c-kit protein level measured by flow cytometry
in immunophenotypically defined LT-HSCs fromWT or ER-deficient mice. Mean ± SD, n = 2–7. MFI, mean fluorescence intensity. (I) Hematopoietic recovery after
5-fluorouracil (5-FU) challenge of WT or Esr1/ mice previously treated with tamoxifen or vehicle for 4 weeks. Values are means ± SD, n = 3–6. Data are
representative of two independent experiments. In (F), (H), and (I), *p < 0.05, **p < 0.01 (vehicle versus tamoxifen). See also Figures S3 and S4.
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Regulation of Hematopoiesis and MPN by Estrogenstamoxifen treatment prevented the characteristic fibrosis and
osteosclerosis of the BM associated with advanced disease
(Figure 4D). Although—as expected from its bone anabolic ef-
fects—tamoxifen increased cortical bone thickness in both WT796 Cell Stem Cell 15, 791–804, December 4, 2014 ª2014 Elsevier In(data not shown) and JAK2V617F+ mice (Figure 4D), tamoxifen
prevented excessive bone formation inside the BM.
To further investigate therapeutic benefits,micewith advanced
disease (1,806 ± 542 3 103 platelets/ml) were administeredc.
Figure 4. Tamoxifen Treatment Blocks the Progression of Myeloproliferative Neoplasms in Mice
(A) Hematological parameters over time in peripheral blood frommice transplanted withMx1-cre;JAK2V617F or control BM cells, treated with tamoxifen or vehicle
(Figure S4A). Dots represent the mean. n = 8–10 (until week 12) or n = 4 (from week 16). Data are representative of two independent experiments.
(B and C) Representative images and weight of spleens frommice transplanted with JAK2V617F+ or control BM cells, sacrificed 13weeks posttransplant (i.e., after
9 weeks of tamoxifen/vehicle treatment).
(D) Reticulin fiber (top) and Van Gieson (bottom) stainings of BM sections from mice transplanted with Mx1-cre;JAK2V617F BM cells, sacrificed 34 weeks
posttransplant (i.e., after 30 weeks of treatment). Results are representative of n = 3–5 animals/group. Magnification: 2003 (top), 1003 (bottom).
(E) Hematological parameters in peripheral blood of mice transplanted with Mx1-cre;JAK2V617F or control (WT) BM cells, treated with tamoxifen/vehicle for
4 weeks at thrombocytosis stage (9 weeks after transplantation). Tamoxifen doses (mg/kg/day, 3 times/week) are indicated.
In (C and E), horizontal lines represent the mean. *p < 0.05, **p < 0.01, ***p < 0.001 (vehicle versus tamoxifen). See also Figure S5.
Cell Stem Cell
Regulation of Hematopoiesis and MPN by Estrogenstamoxifen for 4 weeks. Treatment significantly reduced leukocyte
and platelet counts and delayed the decrease in red cell param-
eters in peripheral blood characteristically associated with dis-
ease progression (Figure 4E and data not shown). Treatment of
thrombocytotic mice with a 10-fold lower dose of tamoxifen,Cellcomparable to the one chronically administered to healthy
women in breast cancer prevention regimens, caused similar
reductions in leukocyte and platelet counts and maintained
normal red cell parameters (Figure 4E). Low-dose tamoxifen
treatment of disease-free control mice only caused very mildStem Cell 15, 791–804, December 4, 2014 ª2014 Elsevier Inc. 797
Figure 5. Tamoxifen Prevents JAK2V617F+ HSPC Expansion by Restoring Normal Apoptosis Levels
(A) Number of colony-forming units in BM and spleen, and (B) immunophenotypically defined BMHSPCs in mice treated as in Figure 4A and sacrificed 13 weeks
posttransplant (i.e., after 9 weeks of treatment). BM data correspond to one tibia, one femur, and one iliac crest. n = 4. (C) Hematological parameters over time in
secondary recipients of tamoxifen- or vehicle-treated JAK2V617F+ BM cells. Lethally irradiated, untreated C57BL/6J mice received 23 106 pooled BM cells from
mice in (A) and (B). n = 3–7. (D) Fraction of apoptotic HSPCs in the BM of mice in (A) and (B). Data are means ± SD, n = 4. NA, not available due to the very low cell
number. *p < 0.05, **p < 0.01, ***p < 0.001 (vehicle versus tamoxifen).
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Regulation of Hematopoiesis and MPN by Estrogensthrombocytopenia (904.8 ± 74 versus 1,146 ± 783 103 platelets/
ml) and neutropenia (0.60 ± 0.09 versus 0.92 ± 0.163 103 neutro-
phils/ml; tamoxifen versus vehicle). These results suggest that
tamoxifen, at a similar dose used for the treatment of other dis-
eases, might be useful to treat MPNs at various stages.
Tamoxifen Prevents JAK2V617F+ HSPC Expansion by
Restoring Normal Apoptosis Levels
Since MPNs are driven by mutant HSCs, we asked whether
tamoxifen-induced MPN blockade was due to its effects on
mutated HSPCs. JAK2V617F+ HSPCs (LT-HSCs, ST-HSCs,
MPPs, and lin c-kit+ Sca-1) expressed Esr1 mRNA at levels
similar to theirWT counterparts, while Esr2 expression was prac-
tically undetectable (data not shown). Remarkably, tamoxifen
treatment decreased HSPC numbers in the BM of JAK2V617F+798 Cell Stem Cell 15, 791–804, December 4, 2014 ª2014 Elsevier Inmice to the normal values found in untreated controls and signif-
icantly decreased their splenic infiltration (Figures 5A–5B and
S5G). Like in disease-free mice, MPPs were the most affected
HSPC, whereas LT-HSCs were less susceptible (Figure 5B).
Secondary recipient animals transplanted with BM cells from
tamoxifen-treated MPN mice showed delayed disease develop-
ment and consistently low leukocyte/platelet counts, suggesting
at least a partial elimination of MPN-initiating cells (Figure 5C).
We next investigated whether these effects were caused by
changes in cell death or proliferation. Tamoxifen modestly in-
hibited JAK2V617F+ HSPC cycle progression (Figure S5H).
JAK2V617F confers a survival advantage to HSPCs that favors
their accumulation (Kralovics et al., 2005). While mutant HSPCs
exhibited comparatively lower apoptosis than their WT counter-
parts, tamoxifen increased the apoptotic fraction of everymutantc.
Figure 6. JAK2V617F+ HSPCs Are More Susceptible to Estrogens than Normal HSPCs
(A–C) Contribution of the JAK2V617F+ clone to different hematopoietic lineages, measured as GFP chimerism in (A) peripheral blood, (B) BM and spleen, and (C)
BM HSPCs of C57BL/6J mice competitively transplanted with equal numbers of WT and Mx1-cre;JAK2V617F;Rosa-gfp BM cells and treated with tamoxifen/
vehicle for 100 days.
(D) Human leukocyte chimerism in peripheral blood of NSGmice transplantedwith humanCD34+ cells from JAK2V617F+MPNpatients and treatedwith tamoxifen/
vehicle for 4 weeks. (E) Number of hematopoietic (hCD45+) and myeloid (hCD45+ hCD33+) human cells (per two tibiae, one femur, and two iliac crests), and (F)
fraction of apoptotic (Annexin V+) hCD45+ cells in the BM of mice in (D), analyzed after 5 months of treatment. n = 8–10.
In (A), (C), and (F), data are means ± SD. In (B), (D), and (E), horizontal lines represent the mean. *p < 0.05, **p < 0.01. See also Figure S6.
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Regulation of Hematopoiesis and MPN by EstrogensHSPC subset to WT levels (Figure 5D). Thus, tamoxifen can
block MPN progression by abrogating the survival advantage
of mutated HSPCs and normalizing their numbers.
JAK2V617F+ HSPCs Are More Susceptible to Estrogens
than Normal HSPCs
To compare the susceptibility of JAK2V617F+ and normal HSPCs
to tamoxifen treatment, male mice were transplanted with equal
numbers of BM cells from WT mice and Mx1-cre;JAK2V617F;
Rosa-gfp mice and were treated with tamoxifen/vehicle for
100 days. These mice developed MPNs similar to recipients ofCellnoncompetitive transplants, and tamoxifen also prevented their
leukocytosis, thrombocytosis, erythrocytosis, and extramedular
hematopoiesis, associated with reduced HSPC numbers in BM
and spleen (Figures S6A–S6F). Most importantly, tamoxifen
decreased the contribution of GFP+ (JAK2V617+) cells to the
megakaryocytic lineage in blood, BM, and spleen, and reduced
the mutant clone chimerism in circulating leukocytes (Figures 6A
and 6B), indicating a more pronounced effect on mutant HSPCs.
This effect was not observed in the erythroid lineage, consistent
with the unaltered number of erythroid progenitors in the BM of
treated animals (Figure S6F). Tamoxifen also decreased theStem Cell 15, 791–804, December 4, 2014 ª2014 Elsevier Inc. 799
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Regulation of Hematopoiesis and MPN by Estrogensproportion of mutant HSPCs in the BM (Figure 6C). These results
demonstrate that tamoxifen preferentially targets JAK2V617F+
HSPCs and facilitates hematopoietic recovery from normal
HSPCs.
To further assess the safety of tamoxifen treatment, we moni-
toredmice transplantedwithWT cells and treatedwith tamoxifen
for 27 weeks. After this prolonged treatment, tamoxifen-treated
mice showed virtually normal blood counts (only platelets were
significantly decreased, but remained within normal values; Fig-
ure S6G). Interruption of tamoxifen treatment for 4 weeks
normalized neutrophil and platelet counts (Figure S6H). Thus,
tamoxifen treatment does not have significant detrimental ef-
fects on normal hematopoiesis.
Tamoxifen Causes In Vivo Apoptosis of Human
JAK2V617F+ HSPCs in a Xenograft Model
To investigate the therapeutic effect of tamoxifen using an in vivo
model of the human disease, CD34+ cells from JAK2V617F+ MPN
patients were transplanted into immunodeficient NOD scid
gamma (NSG) mice. Upon stable engraftment of the cells,
mice were kept under tamoxifen or regular diet for 3 months.
Tamoxifen significantly decreased the human cell chimerism in
peripheral blood already after 4 weeks of treatment (Figure 6D),
consistent with reduced number of human hematopoietic and
myeloid-lineage cells in the BM (Figure 6E). This was associated
with significant induction of apoptosis (Figure 6F), thus recapitu-
lating the results obtainedwith themurineMPNmodel. Together,
the data support an antineoplastic action of tamoxifen in both
mouse and human MPNs, mediated by a proapoptotic effect
on malignant HSPCs.
Tamoxifen Enhances the Effect of Chemotherapy in
MLL-AF9-Induced Acute Myeloid Leukemia
To investigate the potential therapeutic targeting of ER signaling
in a different hematological malignancy, we tested the ability
of tamoxifen to sensitize chemoresistant MLL-AF9-induced
acute myeloid leukemias (AMLs) to conventional chemotherapy.
Mice transplanted with rtTA;MLL-AF9BM cells received different
combination regimens of tamoxifen and/or chemotherapy (Fig-
ure S7A). Shortly after chemotherapy, tamoxifen- and vehicle-
treated mice had similar numbers ofMLL-AF9+ cells and HSPCs
(Figures S7B–S7D). However, the reappearance of circulating
leukemic cells after chemotherapy was delayed in tamoxifen-
treatedmice (Figure 7A). Although the aggressiveness of this dis-
easemodel led to similar lethality (Figure S7E), tamoxifen-treated
mice showed fewer leukemic cells in BM, spleen, and blood
(Figure 7B). Both 4OHT and E2 directly induced apoptosis of
murineMLL-AF9+ blasts in vitro (Figure 7C) and 4OHT enhanced
the proapoptotic effect of low-dose cytarabine on these cells
(Figure S7F), suggesting a direct proapoptotic action of tamox-
ifen on leukemic cells. In vitro 4OHT treatment also induced
apoptosis of human MLL-AF9+ AML cells (Figure 7D).
Since estrogens are metabolic regulators and many tamox-
ifen-induced gene expression changeswere related tometabolic
pathways, we studied whether tamoxifen might compromise
leukemic blast metabolism. Estrogen-induced apoptosis of
MLL-AF9+ cells was preceded by a rapid, dose-dependent inhi-
bition of mitochondrial respiration: both 4OHT and E2 rapidly
decreased the baseline oxygen consumption rate and the spare800 Cell Stem Cell 15, 791–804, December 4, 2014 ª2014 Elsevier Inrespiratory capacity. This metabolic effect was specific and re-
versible because themaximal respiratory capacity and the glyco-
lytic flux (ECAR) remained unaltered (Figure 7E).
These results show that tamoxifen can induce apoptosis of
murine and human AML cells and can also sensitize leukemic
cells to conventional chemotherapy.
DISCUSSION
Despite the known effects of estrogens on other cell types and
their potential impact on the HSC niche through control of
bone metabolism, whether sex hormones play a direct role in
the regulation of primitive normal and leukemic hematopoietic
cells has remained unclear. Estrogens have been shown to in-
crease, decrease, or not affect HSPC numbers, depending on
the methodology/markers used to define the cell populations (Il-
ling et al., 2012; Jilka et al., 1995; Nakada et al., 2014; Thurmond
et al., 2000). On the other hand, epidemiological data consis-
tently show higher incidences of hematological malignancies
(both lymphoid andmyeloid) in men compared to women (Amer-
ican Cancer Society, 2013; Cancer Research UK, 2013), strongly
suggesting a role for sex hormones in hematological cancer pre-
disposition, and therefore in the regulation of HSPCs, fromwhich
these neoplasias arise.
Here we described high-level expression of ERa in HSPCs and
differential effects of ERa activation on HSPC proliferation and
survival. While the more proliferative MPPs were most prone to
apoptosis, the relatively quiescent LT-HSCs entered the cell cy-
cle upon ER activation, resulting in loss of both self-renewal sig-
natures and the ability to reconstitute hematopoiesis after stress
(which requires activation of quiescent HSCs). The effects of
tamoxifen were dependent on ERa activation in HSPCs and
were cell autonomous, because they were abolished in Esr1/
HSPCs in vivo, even in a WT microenvironment. Increased
expression of E2-induced genes by tamoxifen suggests that it
acts as an ER agonist in HSPCs, as opposed to its antiestrogenic
action on breast cancer cells. ER activation in LT-HSCs was
accompanied by activation of the Myc transcriptional program,
previously associated with HSC differentiation and consistent
with the effects on self-renewal and poststress recovery. Myc
is a transcriptional target of estrogens (Dubik and Shiu, 1988)
and the effects of tamoxifen on hematopoietic progenitors
seem at least partially dependent on Myc.
Our findings are consistentwith recent observations that HSCs
divide more frequently in females and under conditions of high
estrogen levels (Nakada et al., 2014); however, our data suggest
more diverse effects of estrogen signaling onHSPC survival, pro-
liferation, self-renewal, Myc activation, and stress response, and
they demonstrate differential effects in various HSPC subsets.
Based on the modulatory effects of ER activation on normal
HSPC survival, quiescence, and self-renewal, we hypothesized
that this pathway might exhibit therapeutic potential in hemato-
logical neoplasias. Indeed, tamoxifen alone blocked the devel-
opment of JAK2V617F+MPNs by reestablishing normal apoptosis
levels in malignant HSPCs, which are otherwise protected from
cell death. Notably, tamoxifen could also rescue leukocytosis
and thrombocytosis when administered at an advanced disease
stage, at a similar dose as the one used clinically for breast can-
cer prevention.c.
Figure 7. Tamoxifen Reduces Leukemic Burden in a Mouse Model of MLL-AF9-Induced Acute Myeloid Leukemia
(A) Leukocyte counts over time in peripheral blood from C57BL/6J mice transplanted with rtTA;MLL-AF9;CD45.1 and WT BM cells, treated as in Figure S7A.
Values indicate mean ± SEM. n = 5–7 (until day 32), n = 3 (from day 41). *p < 0.05 (chemo versus TAM+chemo). Results are representative of two independent
experiments.
(B) Leukemic burden in BM, spleen, and blood of mice treated as in (A), sacrificed when moribund. Data are means ± SD. n = 3–9. Chemo, chemotherapy; ++
indicates the ‘‘intensive’’ regimen. *p < 0.05. Data were pooled from two independent experiments.
(C and D) Fraction of apoptotic mouse (C) and human (D) MLL-AF9+ BM blasts treated in vitro with 4OHT or E2 for 48 hr. Data indicate mean ± SD of triplicate
measurements.
(E) Baseline and maximal respiratory capacity, expressed as oxygen consumption rate (OCR); spare respiratory capacity (SRC); and extracellular acidification
rate (ECAR) in murine MLL-AF9+ BM blasts treated with the indicated concentrations of 4OHT or E2 for 2 hr. Data are means ± SD of five or six replicates (one
representative experiment out of three is shown).
In (C)–(E), *p < 0.05, **p < 0.01 (treated versus untreated). See also Figure S7.
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HSPCs, we provided multiple evidences demonstrating higher
susceptibility of JAK2V617F+ HSPCs: (1) reduction of the mutant
clone chimerism in competitive transplantation experiments; (2)
differential effects on extramedullary HSPC infiltration (elimina-
tion of splenic HSPCs inMPN-affected mice versus HSPCmobi-
lization to the spleen in control mice); (3) higher apoptosis in
JAK2V617F+ LT-HSCs than in their normal counterparts; and (4)
virtually normal hematological parameters in tamoxifen-treated
WTmice, with only mild, reversible thrombocytopenia/neutrope-
nia. Similar mild side effects were noted since the initial breast
cancer trials (Gong et al., 2011; Lerner et al., 1976), but the pos-
itive efficacy/safety profile of tamoxifen has allowed us to extendCellits use from breast cancer treatment to prevention (Cuzick et al.,
2013). The above observations argue for the feasibility of using
tamoxifen in MPN therapy with acceptable safety and relatively
low toxicity.
In addition, tamoxifen enhanced the response of MLL-AF9-
induced AMLs to conventional chemotherapy in vivo, reducing
leukemic burden despite the aggressive course of the disease.
Tamoxifen induced apoptosis of murine and human MLL-AF9+
cells, preceded by rapid inhibition of mitochondrial respiration.
Hormone replacement therapy has been previously associ-
ated with a slightly decreased risk of developing AML (Ross
et al., 2005). Esr1 gene polymorphisms have been suggested
to confer AML susceptibility (Anghel et al., 2010). The Esr1Stem Cell 15, 791–804, December 4, 2014 ª2014 Elsevier Inc. 801
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man et al., 1996; Hess et al., 2008), its methylation status might
predict prognosis (Yao et al., 2010), and its re-expression after
hypomethylating therapy correlates with clinical response
(Blum et al., 2007).
Finally, it is important to note thewide use of tamoxifen in exper-
imental research to induceCreER recombinaseactivity.Theeffects
of tamoxifen on HSPCs have probably remained underapp-
reciated due to its relatively low impact in normal blood counts.
However, our data call for caution when interpreting results, since
even in the absence of any genetic modification, tamoxifen-
treated animals exhibit altered baseline HSPC populations and
may show, dependingon the experimental conditions, someother
abnormal hematological parameters. A previous study has raised
similar concerns about polyI-polyC-inducible models due to the
proliferative effect of interferon-a on HSCs (Essers et al., 2009).
Together, these data reveal differential roles of estrogen
signaling in the regulation of primitive normal and malignant he-
matopoietic cells. They also demonstrate that targeting this
pathway with a clinically approved ligand, at doses with proven
acceptable toxicity profiles in humans, provides a potential ther-
apeutic strategy for a set of neoplasias currently without defini-
tive cure.
EXPERIMENTAL PROCEDURES
Mice and Pharmacological Treatments
Allmouseproceduresconformed toEUDirective2010/63EUandRecommenda-
tion 2007/526/EC regarding the protection of animals used for experimental and
other scientific purposes, enforced in Spanish law under Real Decreto 53/2013.
Animals were housed in specified-pathogen-free facilities. Age-matched, WT
C57BL/6J (CD45.2+), B6.SJL (CD45.1+), Esr1/ and Esr2/ (Jackson Labora-
tory), Pol2-creERT2 (Guerra et al., 2003), Myc-floxed (de Alboran et al., 2001),
and NSG mice were used for in vivo treatments and as donor/recipients in BM
transplantation assays. MPN was induced by transplantation of 2 3 106 polyI-
polyC-inducedMx-Cre;JAK2V617F BM cells into lethally irradiated C57BL/6J re-
cipients. AMLwasmodeledby transplantation of 106 rtTA;MLL-AF9BMcells fol-
lowed by doxycycline administration. For short treatments (up to 1 month), mice
were injected i.p. with 14 or 140 mg/kg of tamoxifen or vehicle (corn oil), three
times per week on alternate days. For longer treatments, mice were fed with
tamoxifen-containingdietTM400 (Harlan)after the lastof four tosix i.p. injections.
Competitive Repopulation Assays
Recipient mice (C57BL/6J or B6.SJL) were lethally irradiated (137Cs source,
12 Gy whole-body irradiation, split dose 6.0 + 6.0 Gy, 3 hr apart) prior to BM
transplant. For AML/MPN experiments, recipients received transplants as
described above. For competitive repopulation assays, CD45.2+ BM cells
were transplanted into CD45.1+ recipient mice or vice versa, mixed with
competitor BM cells isogenic to the recipient (typically 2 3 105 cells; see Fig-
ure Legends for details). Peripheral blood chimerism was assessed by flow
cytometry every 2–4 weeks, and recipients were sacrificed 4 months post-
transplant for the analysis of long-term BM engraftment.
The models of hematological neoplasia and the methods for hematopoietic
recovery after myelotoxic stress, flow cytometry and fluorescence-activated
cell sorting, hematopoietic progenitor assays and other in vitro assays, RNA
sequencing and bioinformatic data analysis, western blot, and histological
and statistical analysis are described in detail in the Supplemental Experi-
mental Procedures.
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